LISS enables immune evasion of colorectal cancers irrespective of MSI status Authors: Qingyu Lin, Xingwen Wang, Weixu Zhao, Shiying Song, Yi Zhang, Jiangwen Ma, Tianyu Li, Yuhan Wei, Minqiao Lu, Guixue Hou, Meiqi Wang, Hao Liu, Shanliang Zheng, Olga Burenina, Zhiyuan Xiang, Li Li, Jiaqi Zhu, Ying Hu Published: 2026 ABSTRACT AbstractDespite being hailed as a significant advancement in cancer treatment, immune checkpoint blockade (ICB) has not yielded favorable outcomes in colorectal cancer, both in approximately 85% of cases characterized by microsatellite stability (MSS) and approximately 50% of microsatellite instability (MSI) cases. How ICB efficiency in colorectal cancer treatment can be improved remains unclear. Here, we identify a new immunoregulatory long non-coding RNA (lncRNA) gene named lncRNA of IFN-γ-signaling suppressor (LISS). LISS expression is increased in colorectal cancers and is linked to poor prognosis, as well as a high CD8+ score. Functional studies reveal that LISS impairs T cell-mediated cytotoxicity, regardless of MSS/MSI status. Mechanistically, LISS interacts directly with the kinase regulatory domain in calmodulin-dependent kinase (CamK)IIγ through a microdomain containing two independent RNA stem-loops. This interaction prevents the binding and phosphorylation of its substrate signal transducer and activator of transcription1 (STAT1) at serine(S)727, a modification necessary for optimal activation of STAT1 and the subsequent major histocompatibility complex I (MHC-I) gene expression. Analysis of human colorectal cancer samples reveals significant inverse correlations between LISS and pS-STAT1 or MHC-I. The knock-in of LISS in intestinal epithelium promotes adenoma development in Apcmin/+ mice. LISS antisense oligonucleotide (ASO)-based therapies enhance the responses of both MSS and MSI colorectal cancers to ICB in vivo, mainly by restoring MHC-I expression. Therefore, we have identified the previously uncharacterized lncRNA LISS to be a regulator of T cell immunity. Targeting it may be an effective therapeutic strategy to improve ICB in colorectal cancers with varying MSI characteristics.Subject terms: Tumour immunology, Tumour immunology Introduction Cancer immunotherapy success hinges on overcoming immune evasion, with immune checkpoint blockade (ICB) being a primary strategy. While effective in melanoma and non-small-cell lung cancer, ICB often fails in colorectal cancer.1,2 Approximately 85% of colorectal cancer cases are microsatellite stable (MSS) and highly resistant to ICB, partly due to low tumor mutational burden and limited neoantigens.3 However, ICB resistance is not confined to MSS cases. Even in microsatellite instable (MSI) cases, which typically have a higher mutational burden, about 50% of patients still develop primary or secondary ICB resistance.4 This highlights that factors beyond the tumor’s mutational load also influence the response to ICB. Disruptions in the interferon (IFN)-γ signaling pathway—often caused by mutations in IFNGR1/2, JAK1/2, or β2M—are frequently associated with clinical resistance to immune checkpoint blockade (ICB).5 Effector T cells secrete IFN-γ, which activates the JAK/STAT pathway and induces IFN-stimulated genes (ISGs) to enhance antigen processing and immune recognition.6,7 While this explains the link between IFN-γ impairment and ICB resistance, such genetic dysfunction is only one contributing factor.8,9 The mechanisms governing IFN-γ pathway activation remain incompletely understood. Moreover, IFN-γ also upregulates immune checkpoint molecules, creating a feedback loop that limits T cell activity and can be co-opted by tumors for immune evasion.10 An optimal anticancer strategy would therefore selectively enhance the antitumor effects of IFN-γ signaling without inducing checkpoint gene expression—a goal that requires deeper insight into tumor-immune regulation. Long non-coding RNAs (lncRNAs) constitute the most abundant class of non-coding transcripts in mammalian cells, exhibiting considerable diversity in size, sequence, structure, and function. LncRNAs regulate gene expression through interactions with proteins and nucleic acids in both the nucleus and cytoplasm, mediated by specific RNA sequences or structural motifs.11 Recent evidence underscores the critical role of lncRNAs in antitumor immunity, where they modulate adaptive and innate immune responses.12 For instance, the lncRNA LIMIT (lncRNA inducing MHC-I and immunogenicity of tumor), identified by Zou et al., functions as an immunogenic lncRNA that promotes cancer immunogenicity.13 In contrast, LINC00973 supports tumor growth by stabilizing CD55 and CD59, thereby inhibiting CD8⁺ T cell activation.14 Another notable example, the cytoplasmic lncRNA IRENA (IFN-responsive nuclear factor-κB activator), is expressed in macrophages and contributes to anticancer immunity following chemotherapy.12 Collectively, these findings emphasize the substantial involvement of lncRNAs in antitumor immunity and suggest that elucidating their functions may reveal novel therapeutic strategies to overcome cancer immune evasion and improve the efficacy of ICB. In this study, we analyzed colorectal cancer expression profiles to identify lncRNAs correlated with both T cell immunity and tumor progression. Our investigation led to the discovery of a novel lncRNA, which we designated lncRNA of IFN-γ-signaling suppressor (LISS). Through gain- and loss-of-function studies, we confirmed LISS’s role in dampening T cell responses in both MSI and MSS colorectal cancers. We elucidated its mechanism of action, which entails the suppression of IFN-γ signaling by binding to CamKIIγ. This binding inhibits CamKIIγ-mediated phosphorylation of STAT1 at serine (S)727, consequently reducing the level of MHC-I-mediated antigen presentation. Additionally, LISS was correlated with MHC-I expression levels in human colorectal cancer tissues and was shown to promote the development of intestinal tumors in Apcmin/+ mice. Targeting LISS with ASO delivered via lipid nanoparticles markedly inhibited tumor growth and improved the efficacy of ICB therapy in both MSI and MSS colorectal cancers. These findings highlight the importance of LISS in advancing our understanding of anticancer T cell immunity and its potential as a therapeutic target to augment the effectiveness of ICB in colorectal cancers, irrespective of MSI status. Results RNA expression profiling screens identify LISS as a potential immune regulatory lncRNA in colorectal cancer CD8 score is an indicator of CD8+ T cell infiltration in the tumor microenvironment. To identify potential lncRNA immunoregulators, we first analyzed the association between the levels of reported immunoregulatory lncRNAs and CD8 score.13,15,16 Our data show that they are significantly associated with each other, with the correlation coefficient (r) normally less than −0.2 (Supplementary Table 1). We then conducted a comprehensive genome-wide screening of lncRNA genes with the criteria that the levels of candidates are associated with a CD8 score (r < −0.2). As such, 408 lncRNA genes were identified by analyzing the colorectal cancer transcriptome data sets in The Cancer Genome Atlas (TCGA, Fig. 1a). The immunoregulatory genes are frequently found to be overexpressed in cancers, possibly because they induce immune tolerance, which confers selective advantages as cancers progress and evolve.1,17 With this in mind, we performed a concurrent screen within the same dataset to pinpoint lncRNAs that are potentially related to colorectal carcinogenesis. As shown, 239 lncRNAs were markedly upregulated more than fivefold in colorectal cancer tissues with a P < 0.05 (Fig. 1a, b). Intriguingly, 11 genes were identified by both screening processes (Fig. 1a). Among these, linc00626, hereafter referred to as LISS, was the only gene with significant prognostic implications (Fig. 1c; Supplementary Fig. 1a). LISS is a potential immune regulatory lncRNA in colorectal cancer. a The Venn diagram displays eleven genes by intersecting the lncRNA genes that negatively correlated with CD8 score (Green, R < −0.2) and those that were upregulated in colorectal cancer tissues compared with normal tissues in TCGA data sets (Yellow, T/N > 5). b Relative LISS expression in normal (N) and colorectal tumors (T) in TCGA data sets. c Kaplan–Meier plot of overall survival (OS), grouped by LISS mRNA levels using TCGA data sets. d Relative LISS expression in N and colorectal T in in-house tissues (n = 49) determined by qRT-PCR. e Correlations between LISS levels and tumor stages in the in-house tissue samples. f Experimental design for the dosing schedule time points for treatment groups. g Tumor images (left), weight (right), and volume (bottom) of vector control (Vect.) and LISS-OE MC38 (MSI) and CT26 (MSS) syngeneic tumors with the indicated treatments. h ELISA assay for T cell effector cytokines (IFN-γ and IL-2) in the MC38 and CT26 syngeneic tumor tissues. i Schematic of the OT-I T cells cocultured with MC38-OVA or CMT-93-OVA cells. j, k The viability of MC38-OVA and CMT-93-OVA cells was analyzed by FACS after coculturing at a ratio of 1:4 (MC38-OVA/CMT-93-OVA: OT-I T). CD45- represents the cancer cell, PI+ represents the dead cells in the coculture system. Data are shown as mean ± SD (g, h, n = 5) or mean ± SEM (i, k) from three independent experiments. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant by 2-way ANOVA (bottom, g), 1-way ANOVA (e, g, and h), Student’s t-test (b, d, j, and k), and log-rank test (c) LISS is a gene that maps to chromosome 1 in the human genome. It is conserved in primates but not in other species (Supplementary Fig. 1b). Rapid Amplification of cDNA Ends (RACE) analysis confirmed that the full-length (FL) LISS lncRNA transcript is 1,081 nucleotides (nt) in length, a finding that aligns perfectly with the sequencing data available in the UCSC Genome Browser (Supplementary Fig. 1c). Both computational analysis and a 3′-GFP tagging strategy revealed that LISS has no protein-coding capability (Supplementary Fig. 1d, e). The following qRT-PCR analysis of the expression of LISS in 49 pairs colorectal cancer samples and their adjacent normal controls validated the increased expression of LISS in human colorectal cancer tissues, as revealed by bioinformatics analysis (Fig. 1d). Additionally, this increase was positively correlated with advanced-stage disease (Fig. 1e). Further examination of LISS expression across a variety of cell types including T cells, macrophages, and cancer cells demonstrated a cancer cell-predominant expression pattern (Supplementary Fig. 1f). RT-PCR following cell fractionation of colorectal cancer cells revealed that LISS was localized in both the cytoplasm and nucleus (Supplementary Fig. 1g). FISH analysis of endogenous LISS showed that it is an abundant lncRNA, with estimated copy numbers of approximately 770–1400 per cell in colorectal cancer cell lines with either MSI or MSS states (Supplementary Fig. 1h). These data inspired us to further investigate the possibility that colorectal cancer cells distort the T cell-mediated antitumor immune response by increasing their expression of LISS. LISS expression in colorectal cancer cells attenuates T cell-mediated killing effects To test the hypothesis proposed above, LISS-overexpressing (LISS-OE) murine colorectal carcinoma MC38 (MSI) and CT26 (MSS) cell lines were generated. Both lines exhibited more rapid tumor growth compared with control lines in immune-competent mice (Fig. 1f, g; Supplementary Fig. 2a). This growth advantage was mitigated by the inhibition of T cell activity using an anti-CD8α antibody (Fig. 1f, g). In addition, CD8+ T cell activities were found to be reduced by LISS overexpression, as indicated by the decreased secretion of IL-2 and IFN-γ within tumors (Fig. 1h). This finding was further validated by subcutaneous tumor formation assays in nude mice, which lack functional T cells (Supplementary Fig. 1i–l). These data suggest that LISS expression in cancer cells promotes tumor growth mainly by inhibiting T cell immunity. The ovalbumin (OVA)-derived peptide SIINFEKL, which is known to bind to the MHC-I heavy chain H-2Kb on cell surfaces, can be specifically recognized by OVA-specific C57BL/6-Tg (TcraTcrb) 1100Mjb/J (OT-I) T cells, thereby triggering antigen-specific T cell activation (Fig. 1i).18 To provide further evidence in support of the above finding, we ectopically expressed OVA-derived peptide SIINFEKL in murine colorectal cancer cells, and found that LISS-OE rendered cancer cells more tolerant to OT-I T cell-mediated killing than controls, regardless of MSI status (Fig. 1j, k; Supplementary Fig. 2a). To clarify the functions of LISS in human cells, we introduced LISS into representative human colorectal cancer cell lines (MSI HCT116 and MSS SW620) to establish stable single-cell sublines. Clones exhibiting moderately increased LISS expression (two- to fourfold) were selected for further analysis (Supplementary Fig. 2b). Consistent with the results obtained from murine cells, LISS-OE cancer cells demonstrated enhanced resistance to T cell-mediated cytotoxicity compared with controls in a cell coculture system. This was evidenced by decreased IL-2 and IFN-γ protein secretion into the culture medium (Supplementary Fig. 2c, d) and a reduced CD45-/PI+ cell population (Supplementary Fig. 2e, f). In contrast, siRNAs that specifically targeted endogenous LISS had opposing effects (Supplementary Fig. 2g, h). Notably, all experiments were conducted in both MSI and MSS colorectal cancer models using both murine and human cells, yielding consistent results. Collectively, these findings suggest that overexpression of LISS in cancer cells, regardless of their MSI or MSS status, confers resistance to CD8+ T cell-mediated antitumor immunity. LISS inhibits the activation of JAK/STAT1 signaling and pro-tumor growth by repressing phosphorylation of STAT1 at S727 We next sought to elucidate the molecular mechanisms underlying LISS-regulated T cell immunity in colorectal cancers. To achieve this, we performed in-house RNA sequencing (RNA-seq) analysis, which corroborated the potential association between LISS expression and T cell immunity. As shown, the DEGs were identified in LISS-knockdown (KD) HCT116 and control cells (Fig. 2a) were linked to immune regulatory pathways, including antigen processing and presentation of peptide antigen, T cell-mediated cytotoxicity, and the regulation of CD8+ and alpha−beta T cell activation (Fig. 2b). LISS expression was also negatively related to pathways, such as the activation of immune responses, the IFN-mediated signaling pathway, and the cellular response to type II IFN pathways, as revealed by GSEA (Fig. 2c). Given that the JAK-STAT and antigen processing and presentation pathways are key downstream processes in the type II IFN signaling cascade (Fig. 2d), we proposed based on these bioinformatic analyses that LISS may play a role in regulating the IFN-γ/JAK/STAT signaling pathways and the cellular machinery for antigen presentation. LISS suppresses the JAK-STAT1 pathway. a Volcano plot for the comparison of DEGs between the control (Ctl) and LISS-KD HCT116 cells. Red color is indicative of upregulated genes, and blue is indicative of down-regulated genes. Gene Ontology (GO) (b) and Gene Set Enrichment Analysis (GSEA) (c) analysis of the DEGs identified in (a). d Overall scheme of the IFN-γ-JAK-STAT signaling pathway. e GAS luciferase reporter activities were determined by luciferase reporter assay in the controls (Vect or si-Ctl), LISS-OE or LISS-KD HCT116 cells treated with IFN-γ for 24 h. Representative western blots of key proteins in the JAK-STAT pathway in colorectal cancer cell lines after the indicated treatments (f), or following cell fractionation (g). qRT-PCR analysis of the MHC-I related genes in LISS-OE (h) or -KD (i) HCT116 cells with or without IFN-γ treatment. Data are represented as mean ± SEM derived from 3 independent experiments (e, h, and i). *P < 0.05; **P < 0.01; #P < 0.05; ##P < 0.01 by 1-way ANOVA (e, h, and i) The activation of the JAK/STAT pathway leads to the transcription of ISGs that contain an IFN-γ activation site (GAS) motif in their promoter regions.19 To experimentally validate the involvement of LISS in regulating IFN-γ/JAK/STAT signaling, we generated a luciferase reporter driven by the GAS motif. As anticipated, there was a significant increase in GAS luciferase reporter activity following IFN-γ treatment. The overexpression of LISS reduced IFN-γ-induced reporter activity to approximately 50% of that in controls, while LISS-KD significantly increased it (Fig. 2e). Surprisingly, LISS did not have any significant impact on IFN-γ-induced phosphorylation cascades, such as the levels of phospho-JAKs (p-JAKs) and phospho-tyrosine STAT1/3/5 (pY-STAT1/3/5), which are essential for transducing extrinsic IFN-γ signaling into the nucleus (Fig. 2f). By a more comprehensive literature research, we noted that the second phosphorylation (pS) at S727 in STAT1 and STAT3 have been also shown to be required for the optimal activation of these transcription factors.20 Although this modification has not garnered sufficient attention, our data show that the expression of LISS significantly inhibited the induction of pS-STAT1 by IFN-γ in several colorectal cancer cell lines with different MSI statuses, but had no impact on pS-STAT3 status (Fig. 2f; Supplementary Fig. 3a, b). Accordingly, LISS was found to reduce IFN-γ-induced pS-STAT1 in the nucleus (Fig. 2g) and also inhibited the mRNA levels of STAT1 target genes, including genes involved in antigen processing and presentation (such as HLA-ABC, HSPA5, CALR, and TAP1) and other typical downstream target genes, such as IFIT1, IFI44, and IRF1 (Fig. 2h, i; Supplementary Fig. 3c, d). Notably, in addition to those antitumor effectors expressed in cancer cells, PD-L1 and PD-L2 represent downstream target genes of the IFN-γ/JAK/STAT1 signaling pathway that blunts T cell immunity in a feedback loop.21,22 Interestingly, LISS had no impact on the expression of these genes under the same conditions (Supplementary Fig. 3e). To determine whether pS727-STAT1 governs the pro-tumor effect of LISS, we established MC38 STAT1 KO cells re-constituted with either wild-type STAT1, STAT1-WT, or pS727 mimic mutant, STAT1-S727D, with or without LISS overexpression. Subcutaneous colorectal tumor growth assays revealed that STAT1-S727D inhibited tumor growth, as expected, the pro-tumor effect of LISS was significantly compromised, although not completely abolished, in STAT1-S727D expressing MC38 tumors (Supplementary Fig. 3f–i). These findings suggest that LISS restricts the activation of the IFN-γ/JAK/STAT1 axis without changing ICB genes, leading to increased tumor growth by suppressing pS-STAT1 activation. LISS restrains STAT1-regulated MHC-I expression to evade T cell immunity As shown above, LISS levels are associated with antigen processing and presentation signaling activity, a key downstream effect of IFN-γ/JAK/STAT1 axis. Given the essential function of antigen processing and presentation in T cell-mediated immunity,23 we further assessed the impact of LISS on MHC-I expression at the protein level. Our results demonstrated that LISS-OE led to decreased levels of H-2Kb and an approximately two- to threefold reduction in SIINFEKL loading in murine cancer cells, which was compromised following STAT1 KD (Fig. 3a, b). These findings were further validated using human cell models. As shown, LISS-OE reduced the protein levels and cell surface presentation of MHC-I molecules in both MSI and MSS human colorectal cancer cells (Supplementary Fig. 4a, b). Conversely, KD of endogenous LISS had the opposite effect (Supplementary Fig. 4c, d). Consistent with previous reports, inhibition of the expression of STAT1 decreased IFN-γ-induced MHC-I expression, and also abolished the effect of LISS (Supplementary Fig. 4a, b). These data indicate that LISS regulates the expression and antigen-presenting ability of MHC-I molecules, mainly through STAT1. LISS impairs antitumor immunity via the downregulation of MHC-I expression. Cell surface SIINFEKL H2-Kb in MC38-OVA (a) and CMT-93-OVA (b) cells was determined by FACS (left) (MFI, mean fluorescence intensity). The expression of MHC-I and STAT1 was detected by Western blot (right). Control and B2m KD MC38-OVA (c) and CMT-93-OVA (d) cells cocultured with OT-1T cells at a ratio of 1:4 (MC38-OVA/CMT-93-OVA: OT-1 T). Cell death was measured by PI staining in CD45− tumor cells. Tumor volume, tumor image, tumor weight of MC38-OVA (e–g) or CMT-93-OVA (h–j) syngeneic tumors with LISS-OE or B2m KD in OT-1 mice (n = 5). Representative western blots of MHC-I from MC38-OVA (k) and CMT-93-OVA (l) syngeneic tumor tissues. Data are presented as mean ± SD (e–j), or mean ± SEM derived from three independent experiments (a–d). *P < 0.05; **P < 0.01; NS, not significant by 2-way ANOVA (e and h), 1-way ANOVA (a–d, g, and j) B2m is a beta chain of MHC-I molecules and plays a crucial role in the functionality of MHC-I complexes.24 To determine whether LISS-mediated MHC-I modulation is involved in LISS-induced immune tolerance, we first targeted B2m expression in MC38-OVA and CMT-93-OVA mouse cells. As expected, B2m KD reduced the impact of OT-1 T cell-mediated cell killing in both cell types in vitro, while concurrent LISS-OE resulted in no further effect on T cell immunity (Fig. 3c, d). In vivo experiments showed that LISS-OE MC38-OVA and CMT-93-OVA tumors grew faster than control tumors in OT-I mice (Fig. 3e–j). The KD of B2m resulted in accelerated tumor growth, and also reduced the differences in tumor weight and volume between the control and LISS-OE tumors (Fig. 3e–j). Western blot analysis confirmed that LISS inhibited the expression of MHC-I in MC38-OVA and CMT-93-OVA tumors (Fig. 3k, l). In addition, LISS’s ability to blunt antitumor immunity was shown to be MHC-I-dependent in human cell lines with either MSI or MSS characteristics (Supplementary Fig. 4e, f). Overall, LISS suppressed antitumor immunity primarily by inhibiting STAT1-regulated expression of MHC-I molecules in cancer cells. LISS physiologically binds to CamKIIγ via a double stem-loop structure, thereby inhibiting the IFN-γ/JAK/STAT1 signaling axis by suppressing pS-STAT1 Interaction with proteins is a well-established mode of action of lncRNAs.25 To elucidate the molecular mechanisms of LISS’s action, we conducted an in vitro RNA pull-down assay using in vitro-synthesized Biotin-sense-LISS and Biotin-antisense-LISS control, together with HCT116 cell lysates in vitro. The proteins in the cell lysates that co-precipitated with Biotin-LISS or Biotin-antisense-LISS were analyzed by mass spectrometry (Supplementary Fig. 5a). We identified 11 kinases or 10 phosphatases using a fold-change threshold of more than 1.5 in the Biotin-sense-LISS group relative to the Biotin-antisense-LISS group (Supplementary Fig. 5b). Of note, CamKIIγ was the only candidate in the list that has been reported to catalyze pS-STAT1 (Supplementary Fig. 5b).26 The interaction between LISS and CamKIIγ was further confirmed by an LISS RNA pull-down assay (Supplementary Fig. 5c). In contrast, the interactions between LISS and other core components of the JAK/STAT pathway, such as STAT1 and JAK1, were either weak or undetectable under the same conditions (Supplementary Fig. 5c). We then speculated that LISS may repress pS-STAT1 by inhibiting CamKIIγ. As expected, the induction of pS-STAT1 by IFN-γ was mitigated by CamKIIγ KD or its inhibition with KN93 and W7 (Fig. 4a; Supplementary Fig. 5d). Interestingly, treatment with these agents also eliminated the inhibitory effects of LISS on pS-STAT1 (Fig. 4a; Supplementary Fig. 5d).27 In contrast, despite having been reported to be a substrate of CamKIIγ,28 the expression of pS-STAT3 was reduced following CamKIIγ KD or chemical inhibitor treatment; however, LISS did not affect pS-STAT3 expression under these conditions. (Fig. 4a; Supplementary Fig. 5d). In addition, LISS-mediated suppression of pS-STAT1 and GAS luciferase reporter activity, as well as key downstream target gene expression, were abolished following inhibition of CamKIIγ (Fig. 4b; Supplementary Fig. 5e, f). This effect was found to be able to restore by wild-type (WT) CamKIIγ, but not by a kinase activity-defective CamKIIγ mutant (Fig. 4b, c). LISS inhibits the JAK-STAT1 pathway by physiologically binding to CamKIIγ via a double stem-loop structure. a Western blots of the key proteins in the JAK-STAT pathway in LISS-OE HCT116 cells with or without CamKIIγ KD. Representative western blots of pY-STAT1 and pS-STAT1 (b) or GAS luciferase reporter activities (c) in CamKIIγ-KD HCT116 cells combined with or without recovery of WT CamKIIγ or active site mutated CamKIIγ. d PLA analysis of the direct bindings between LISS and CamKIIγ in HCT116 cells. e LISS levels were determined by qRT-PCR following CLIP CamKIIγ in HCT116 cells with the indicated treatments. f Prediction of the secondary structure of LISS-F3 (511–860 nt) using RNAfold web server. The F3-4 region (723–860 nt) contains two stem-loop structures (named stem A and stem B) highlighted by circles. The mutations introduced are indicated by squares. g CamKIIγ was co-precipitated by Biotin-LISS-F3-4 (723–860 nt) and the mutants with the defective stem A (MT-stem A) or defective stem B (MT-stem B), or both (MT-stem A + B), by RNA pull-down assay. h The purified GST-tagged full-length (FL) CamKIIγ protein or its truncates pulled down by Biotin-LISS were determined by western blot. Schematic showing CamKIIγ fragmented domain structures. i The model structure of CamKIIγ (273–290 aa)/LISS-F3-4 (723–860 nt) complex predicted by HDOCK docking software. j The interactions between CamKIIγ and STAT1 in HCT116 cells transfected with LISS-F3-4 or its fragments were assessed by co-immunoprecipitation in the presence or absence of IFN-γ treatment. k Representative western blots of pY-STAT1 and pS-STAT1 in HCT116 cells transfected with LISS FL, or the indicated mutants in the presence or absence of IFN-γ treatment. l The GAS luciferase reporter activities were determined by luciferase reporter assay in HCT116 cells transfected with LISS-F3-4 or its mutants in the presence or absence of IFN-γ treatment. m, n Tumor images (left), weight (middle), and volume (right) of Vect, LISS-WT, LISS-MT-stem A + B MC38 (MSI) and CT26 (MSS) syngeneic tumors. Data are represented as mean ± SEM derived from 3 independent experiments (c, e, and l). *P < 0.05; **P < 0.01; ***P < 0.001; NS not significant by 1-way or 2-way ANOVA (c, e, l–n) Given the significant role of CamKIIγ activity in mediating LISS action identified above, we next explored whether the LISS/CamKIIγ interaction is direct using a proximity ligation assay (PLA) and RNA UV crosslinking and immunoprecipitation (CLIP) assay. Both assays demonstrated a physiological interaction between LISS and CamKIIγ in living cells, and their interaction was found to be enhanced by IFN-γ (Fig. 4d, e; Supplementary Fig. 5g). LISS/CamKIIγ binding was abolished by LISS-KD (Fig. 4e; Supplementary Fig. 5g). Purified CamKIIγ bound with in vitro-synthesized LISS in an LISS dose-dependent manner, but not with an antisense LISS control (Supplementary Fig. 5h). These data support the idea that the two molecules interact with each other, and that their interaction is specific and functionally relevant to the activation of IFN-γ signaling. To further define the biochemical mechanisms of LISS/CamKIIγ binding, we generated independent LISS fragments based on secondary structures predicted by RNA fold software (http://rna.tbi.univie.ac.at/cgi-bin/RNAWebSuite/RNAfold.cgi, Supplementary Fig. 5i).29 Using this approach, we initially identified fragment 3 (F3, 511–860 nt) as the key sequence for CamKIIγ binding (Supplementary Fig. 5j), which was further refined to F3-4 (723–860 nt) (Supplementary Fig. 5k). Previous studies have suggested that lncRNAs can interact with proteins through secondary loop structures.12 Interestingly, F3-4 contains two stem-loop structures, named stem A (747–754 nt) and stem B (736–766 nt) (Fig. 4f). We introduced point mutations at specific sites within the stem sequences, as shown in Fig. 4f, to disrupt the individual stem structures. Our data show that mutations at either stem (MT-stem A or MT-stem B) modestly reduced LISS/CamKIIγ binding, whereas a double mutation (MT-stem A + B) completely eliminated it (Fig. 4g). These findings suggest that LISS interacts with CamKIIγ primarily through the dual stem-loop structures. Extensive efforts have also been made to pinpoint the amino acid residues within CamKIIγ that are essential for its interaction with LISS. To this end, a series of truncated mutants were created, informed by the known domain structures of CamKIIγ (Fig. 4h). Utilizing an in vitro RNA pull-down assay, we observed that LISS did not bind to CamKIIγ mutants that lacked the N-terminal half of the regulatory domain, specifically the region spanning 273–290 amino acid (aa) (Fig. 4h). The interaction between LISS and CamKIIγ was further corroborated by molecular docking simulations (Fig. 4i). Intriguingly, the 273–290 aa region includes the substrate binding motif of CamKIIγ. Consequently, overexpression of LISS led to a reduction in the interaction between CamKIIγ and its substrate STAT1, while the MT-stem A + B mutant had no such effect (Fig. 4j), as well as on the levels of pS-STAT1 and the activity of the GAS luciferase reporter (Fig. 4k, l). Furthermore, the T cell-mediated cytotoxicity assay revealed that the MT-stem A + B not only abolished the immunoregulatory effect of LISS but also significantly reduced its pro-tumor activity in a subcutaneous tumor formation assay (Fig. 4m, n; Supplementary Fig. 5l, m). These findings demonstrate that LISS promotes tumor growth primarily through its double stem-loop structure, which suppresses CamKIIγ-induced STAT1 activation. LISS forms a negative feedback loop in response to the activation of IFN-γ/JAK/STAT1 signaling The expression of immune checkpoint molecules is typically upregulated in response to the sustained activation of T cells.30 Given this, we investigated whether LISS, similar to other reported immune checkpoint genes, is responsive to the activation of IFN-γ signaling. Interestingly, IFN-γ significantly upregulated LISS expression in a manner that was both time- and dose-dependent (Fig. 5a; Supplementary Fig. 6a). In addition, we observed similar dynamic changes in the activity of an LISS promoter-driven luciferase reporter under the above-described experimental conditions, while the activity of a luciferase reporter controlled by the LISS 3′-untranslated region remained largely unaffected (Fig. 5b; Supplementary Fig. 6b, c). These findings support the idea that LISS is transcriptionally upregulated by IFN-γ signaling. IFN-γ transactivates LISS via TEAD1. Representative western blot of pS-STAT1 expression, LISS levels in HCT116 cells determined by qRT-PCR (a), and LISS promoter luciferase reporter activities determined by luciferase reporter assay (b) in HCT116 cells treated with 50 ng/ml IFN-γ for the indicated time periods. c Relative binding potentials between different transcription factors and the LISS promoter region were analyzed by the ChIP-Base V3.0 bioinformatic tool. d LISS levels were determined by qRT-PCR in HCT116 cells following KD of the predicted candidate transcription factor genes. LISS levels (e) and LISS promoter luciferase reporter activities (f) in HCT116 cells with or without TEAD1 KD. (g) The binding between the LISS promoter region and TEAD1 was determined by ChIP assay in HCT116 cells after IFN-γ treatment (50 ng/ml for 24 h). h LISS promoter (WT and MT) controlled luciferase reporter activities were determined after transfection of the indicated reporter plasmids to HCT116 cells with or without IFN-γ (50 ng/ml for 24 h). i The luciferase reporter assay of WT (including TEAD1-binding site) and LISS-promoter-Mut (TEAD1-binding site mutation) activities was determined after transfection of the indicated reporter plasmids to HCT116 cells with or without IFN-γ (50 ng/ml for 24 h). Data are represented as mean ± SEM derived from 3 independent experiments (a, b, d–h). *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001; NS, not significant by 1-way or 2-way ANOVA (b, d–i) Interestingly, our data indicate that LISS expression is induced by IFN-γ at a later time point than JAK/STAT1 pathway activation (12 h vs. 0.5 h). Prolonged IFN-γ treatment further resulted in sustained accumulation of LISS, accompanied by a corresponding decline in pS-STAT1 levels (24–48 h, Fig. 5a), suggesting that LISS may function as a feedback inhibitor to attenuate JAK/STAT1 signaling. Notably, STAT1 KD did not affect IFN-γ–induced LISS expression (Supplementary Fig. 6d), implying the involvement of STAT1-independent mechanisms in this regulation. Furthermore, despite LISS’s ability to inhibit Ca2+ signaling-induced CamKIIγ activity,31 its expression levels were not altered by the Ca2+ chelator BAPTA-AM (Supplementary Fig. 6e). This specificity in LISS’s response to immune signaling underscores its potential role in the modulation of immune responses. To predict transcriptional factors that could potentially regulate LISS’s transcription, the ChIP-Base V3.0 bioinformatic tool was applied.32 The analysis identified six candidate transcription factors: MYOD1, HNF4A, SOX2, YY1, TEA domain transcription factor 1 (TEAD1) and CTCF (Fig. 5c). Individual gene KDs revealed that only YY1 and TEAD1 had the ability to promote LISS mRNA expression (Fig. 5d; Supplementary Fig. 6f). However, YY1 KD failed to influence IFN-γ-induced expression of LISS (Supplementary Fig. 6g), while TEAD1 KD completely abolished IFN-γ-induced LISS expression and LISS promoter-driven luciferase reporter activity (Fig. 5e, f). Although TEAD1 expression remained unchanged with IFN-γ treatment, the binding between TEAD1 and the promoter region of LISS increased, as shown by ChIP assay (Fig. 5g; Supplementary Fig. 6h). Two reporters were subsequently generated using the truncated LISS promoter: truncated mutant 1 (MT1) containing the predicted TEAD1-binding motif, and MT2 without the motif (Fig. 5h; Supplementary Fig. 6i). The luciferase activity of MT1 was as effective as that of the FL in response to IFN-γ treatment, while MT2 largely lost its response to IFN-γ (Fig. 5h). Supportively, LISS reporter with TEAD1-binding site mutation (LISS-promoter-Mut) failed to response to IFN-γ treatment (Fig. 5i). Therefore, TEAD1 transcriptionally activates LISS by binding to the TEAD1-binding motif at its promoter region in response to IFN-γ stimulation. LISS promotes intestinal tumor development Given the essential role of LISS in regulating pS-STAT1, we sought out to investigate the association between LISS and pS-STAT1 in human tissues. To this end, we performed qRT-PCR and western blot analysis of these targets in 49 paired human colorectal cancer tissues. The results of quantitative analysis indicated that pS-STAT1 and MHC-I levels were lower in colorectal cancer tissues compared with adjacent normal controls. However, the changes in total STAT1 levels were mild and did not reach statistical significance (Fig. 6a–d). The decreases in pS-STAT1 and MHC-I levels were found to be associated with advanced stages of colorectal cancer (Fig. 6e–g). Additionally, there were negative correlations between LISS expression levels and pS-STAT1 and MHC-I levels (Fig. 6h, i). However, no significant correlation between LISS and total STAT1 expression was identified (Fig. 6j). These data suggested that LISS may have an intrinsic role in repressing pS-STAT1/MHC-I in human colorectal cancer tissues. The expression levels of LISS, pS-STAT1, and MHC-I are associated with each other in colorectal cancer tissues. a–d The levels of pS-STAT1, MHC-I, and STAT1 in human colorectal tumors (T) and their paired adjacent normal controls (N) (n = 49). Representative western blots (a) and quantification of pS-STAT1 (b), MHC-I (c), and STAT1 (d). The correlation of the levels of pS-STAT1 (e), MHC-I (f), and STAT1 (g) in colorectal tumors with stages. Lineal correlation analysis of the LISS expression versus those of pS-STAT1 (h) (P < 0.0001), MHC-I (i) (P < 0.0001), and STAT1 (j) (P < 0.0001) protein expression in colorectal tumors, respectively. Data are presented as mean ± SD derived from 3 independent experiments (b–j). *P < 0.05; **P < 0.01; NS, not significant by paired Student’s t-test (b–d), or 1-way ANOVA (e–g). Correlations were calculated according to Pearson’s correlation (h–j) Loss of MHC-I molecule expression in colorectal cancer is a major cause of immune evasion.33 We thus speculated that LISS overexpression may contribute to the increased development of intestinal tumors. To test this hypothesis, we generated intestinal epithelial-specific LISS knock-in mice on an Apcmin/+ background (Apcmin/+; Villin-CreERT2; LISSflox/flox) on an Apcmin/+ (Supplementary Fig. 7a, b). qRT-PCR demonstrated that LISS expression was selectively induced in colorectal tissue by treating mice with tamoxifen (Supplementary Fig. 7c). Using this model, we observed that LISS expression accelerated intestinal tumor development in Apcmin/+ mice with or without a high-fat diet (Fig. 7a–c; Supplementary Fig. 7d, e). Quantification confirmed a significant increase in average adenoma number upon LISS knock-in (Fig. 7d; Supplementary Fig. 7f). Detailed size distribution analysis further revealed that LISS knock-in promoted adenoma growth, with 81.6% of macroadenoma categorized as size ≥3, compared to 52.6% in controls. (Fig. 7e; Supplementary Fig. 7g). Histological examination further confirmed the ability of LISS in promoting intestinal tumor development (Fig. 7f; Supplementary Fig. 7h). In addition, we detected the increased Ki-67 positive proliferating cells and decreased infiltration of CD8+ T cells, as well as the decreased pS-STAT1 levels in the LISS knock-in adenoma (Fig. 7g–i). Western blot analysis confirmed the inhibitory effect of LISS towards pS-STAT1 and MHC-I in intestinal tissues (Fig. 7j). Accordingly, lifespan was significantly shortened in LISS knock-in mice, as compared to Apcmin/+; Villin-CreERT2 control mice (Fig. 7k). Together, these results emphasize the significance of LISS in the acceleration of intestinal tumor development. LISS promotes the development of intestinal tumors. a Experimental design for the dosing schedule time points for tamoxifen and high-fat diet treatment in the Apcmin/+ mouse model (n = 15 mice per group). b LISS levels were determined by qRT-PCR in small intestine derived from Apcmin/+; Villin-CreERT2 and Apcmin/+; Villin-CreERT2; LISSflox/flox mice. (c) Representative images of the small intestine from Apcmin/+; Villin-CreERT2 and Apcmin/+; Villin-CreERT2; LISSflox/flox mice following high-fat diet treatment. Quantification of the total numbers (d) and classification of size (e) of the adenomas developed in the Apcmin/+; Villin-CreERT2 and Apcmin/+; Villin-CreERT2; LISSflox/flox mice (n = 5), size 1: adenoma diagram <1.5 mm, size 2: ≥1.5 mm<2 mm, size 3: ≥2 mm<2.5 mm, size 4: ≥2.5 mm<3 mm, size 5: ≥3 mm. f H&E-stained sections along the small intestine longitudinal axis in tissues from Apcmin/+; Villin-CreERT2 and Apcmin/+; Villin-CreERT2; LISSflox/flox mice with high-fat diet. Representative images of Ki-67 (g), CD8 (h), and pS-STAT1 (i) staining in the Apcmin/+; Villin-CreERT2 and Apcmin/+; Villin-CreERT2; LISSflox/flox mice adenoma tissues. j Representative western blots of pS-STAT1 and MHC-I in adenoma tissues. k Kaplan–Meier survival plots of the Apcmin/+; Villin-CreERT2 and Apcmin/+; Villin-CreERT2; LISSflox/flox mice (n = 10). Data are presented as mean ± SD (b, d, h). ***P < 0.001; NS, not significant by Student’s t-test (b, d, n = 5 mice per group), log-rank test (k, n = 10 per group) Blockade of LISS signaling improves ICB sensitivity Given the role of LISS in carcinogenesis and the essential role of the IFN-γ/JAK/STAT1 signaling pathway in antitumor immune surveillance,34 we next investigated whether inhibiting LISS could improve T cell-mediated immunity and enhance the efficacy of established ICB, such as anti-PD-1 antibody, in MSI and MSS tumors. To this purpose, two subcutaneous tumor models of colorectal cancer were established by introducing MC38 (MSI) and CT26 (MSS) cells into immunocompetent mice (Fig. 8a). To inhibit LISS, we designed an ASO that specifically targeted LISS, and a lipid nanoparticle-encapsulated LISS-ASO was generated.35 The inhibitory effect was first confirmed in vitro in cultured cells (Fig. 8b) and subsequently assessed in vivo. LISS expression promoted tumor growth and reduced tumor sensitivity to anti-PD-1 therapy. While LISS-ASO showed no effect on tumors lacking endogenous LISS expression, it significantly suppressed the growth of their LISS-expressing counterparts under the same conditions. These results indicate that the antitumor activity of LISS-ASO is primarily mediated through LISS inhibition. In addition, both anti-PD-1 and LISS-ASO monotherapies showed antitumor activity in LISS-expressing MSI MC38 (Fig. 8c–e) and MSS CT26 tumor models. The combination treatment resulted in a more pronounced therapeutic effect, as demonstrated by significant reductions in tumor size and weight (Fig. 8c–h). In LISS-expressing tumors, LISS-ASO extended mouse survival to a milder extent than anti-PD-1 monotherapy, while the combination of both treatments yielded a more pronounced prolongation of survival (Fig. 8j). The body weights of the mice remained stable with these treatments, indicating that the combination therapy was well tolerated (Supplementary Fig. 8a, b). In addition, flow cytometric analysis of the tumor samples revealed an increase in the proportion of IFN-γ+ CD8+ (CD3+CD8+IFN-γ+) T cells in anti-PD-1 antibody or LISS-ASO-treated LISS-expressing tumors, with the combination having a more evident effect (Fig. 8i). Additionally, qRT-PCR and western blot analysis showed that LISS-ASO efficiently suppressed the expression of LISS (Supplementary Fig. 8c, d) and reinstated the expression of MHC-I molecules (Supplementary Fig. 8e–h). These findings suggest that LISS-ASO improves the responsiveness of both MSI and MSS colorectal cancers to anti-PD-1 treatment. LISS-ASO improves the ICB outcome in MSS/MSI colorectal cancer. a Experimental design for the dosing schedule time points for treatment groups (n = 12 mice per group). b LISS levels were determined by qRT-PCR in MC38 and CT26 cells. Tumor images, volume, and weight of MC38 (c–e) and CT26 (f–h) syngeneic tumors. Each dot represents an evaluation in an individual tumor. i FACS of CD8+ IFN-γ+ in CD3+ T cell populations from isolated tumor-infiltrating lymphocytes in MC38 (left) and CT26 (right) syngeneic tumors. j Kaplan–Meier survival curve of mice bearing syngeneic MC38 (upper) and CT26 (bottom) tumors with treatment of IgG or anti-PD-1 antibody and LISS-ASO. k LISS is highly expressed in colorectal cancer cells and is associated with poor prognosis and low CD8 Score. Mechanistic studies show that LISS inhibits IFN-γ signaling by suppressing the expression of ISGs, such as MHC-I, in a STAT1-dependent manner. Specifically, LISS interacts with CamKIIγ via its double stem-loop structure, blocking CamKIIγ from binding to STAT1. This interaction reduces pS727-STAT1 and impairs its transcriptional activity towards MHC-I, ultimately promoting tumor-immune evasion. Additionally, LISS is an intrinsic component of the IFN-γ signaling pathway, as its expression is upregulated by TEAD1 following IFN-γ stimulation. Nanomaterial-encapsulated ASO targeting LISS can degrade LISS, thereby reversing its effects and improving ICB efficiency. Data are shown as mean ± SD (b, d, e, g–i) *P < 0.05; **P < 0.01; ***P < 0.001; NS, not significant by 1-way ANOVA (b, e, h, and i, n = 5 per group), 2-way ANOVA (d and g, n = 5 mice per group), log-rank test (j, n = 7 per group) Discussion Colorectal cancer is one of the most common tumors worldwide and is notoriously resistant to ICB therapies.36 Even patients with MSI tumors (15% of all patients), which generally have higher mutation burdens and tend to have more neoantigens, have a low response rate to ICB treatment.36 This suggests that neoantigen level-independent mechanisms of ICB resistance exist. Here, we identified a previously uncharacterized lncRNA gene, LISS, as inhibiting T cell-mediated immunity independently of the MSI status of colorectal cancers by inhibiting CamKIIγ-mediated STAT1 activation and antigen presentation (Fig. 8k). In contrast to the majority of lncRNA genes identified to date, LISS is relatively abundant, and its levels can be further elevated in response to IFN-γ signaling. In turn, LISS specifically inhibits the activity of STAT1, but not other STATs (although IFN-γ can induce the activation of multiple STATs, such as STAT1, STAT3, and STAT5).37 This is an intriguing observation, because despite having upstream signaling and structural similarities in their abilities to bind consensus DNA sequences in the nucleus, members of the STAT family of proteins produce diverse and even opposing effects in the context of cancer. STAT3 and STAT5 are generally considered oncogenes, while STAT1 inhibits tumorigenesis.38 Our data suggest that LISS mainly inhibits a tumor suppressive branch of the IFN-γ/JAK signaling pathway, without interfering with the oncogenic branch. How LISS fulfills this role remains unclear. Nevertheless, pS-STAT3 is not under the control of CamKIIγ, the direct target of LISS, under our experimental conditions. This is not consistent with a previous report conducted in myeloid leukemia cells, and it is possible that the selective regulation of STATs by LISS is context-dependent.28 Furthermore, pS-STAT1 is required for optimal activation of STAT1, while pY-STAT1 is a conventionally recognized key regulator of STAT1 signaling. The selective regulation of pS-STAT1 by LISS suggests that targeting LISS may enhance STAT1 signaling without causing the toxicity associated with overactivation of pS-STAT1. LISS was recently reported to have a cell-autonomous effect in breast cancer. Our data also suggest that LISS has a CD8⁺ T cell-independent action in vivo, which is consistent with our finding that LISS exerts a mild but statistically significant STAT1 S727-independent pro-tumor function. It will be interesting to further investigate these functions of LISS in future studies. In addition, the IFN-γ signaling pathway enhances MHC-I molecule expression to stimulate antitumor immunity, while also enhancing the PD-L1 checkpoint pathway’s ability to dampen antitumor immunity.39 Notably, our experiments showed that LISS is induced by IFN-γ at a relatively late stage and plays a role in inhibiting the expression of MHC-I molecules, but not of PD-L1. This is another level of selectivity, which further indicates that LISS represents a mechanism that colorectal cancer cells use to block tumor suppression downstream of IFN-γ/JAK signaling. Although the underlying mechanisms may involve a complex regulatory network, our findings suggest that inhibition of LISS significantly enhances T cell immunity and inhibits tumor growth and has the potential for clinical application. Furthermore, although LISS plays a role in regulating Ca2+-modulated CamKIIγ, its activity does not change in response to altered Ca2+ concentrations. These findings indicate that LISS exerts its primary function mainly in the context of the immune response. It can also be concluded that LISS acts as a mediator between immune signals and Ca2+-signaling by forming a complex with CamKIIγ. Our data demonstrate that LISS exerts its effects through a tightly linked double stem-loop structure. This structure enables LISS to bind CamKIIγ at a region containing substrate binding sites. Indeed, LISS inhibits the binding between CamKIIγ and its substrate STAT1. In recent years, RNAs have been structurally and functionally characterized and identified as druggable targets for small molecules for the treatment of several human pathologies, including cancer and viral and bacterial infections.40,41 LISS-ASO is effective in improving the response of colorectal cancers to ICB, regardless of their MSI status. Further investigation is required to determine whether its double stem-loop structure can be targeted by small molecules. In addition, based on the primary sequence screening, it appears that LISS does not have conserved counterparts in other species. Our data suggest that LISS acts through these double stem-loop structures, which suggests that other RNAs with similar loop structures may exert pro-tumor immune evasion effects across different species, something that warrants further investigation. In conclusion, we have identified an immunoregulatory lncRNA, LISS, in colorectal cancer and demonstrated that LISS plays an MSI status-independent role in regulating antigen presentation by repressing CamKIIγ-mediated pS-STAT1. The targeting of LISS potentially represents an effective therapeutic strategy for the reversal of both MSI and MSS colorectal cancer sensitivity to ICB. Materials and methods Tissue samples The 49 pairs of human colorectal cancer tissues and their corresponding adjacent controls were collected from the Third Affiliated Hospital of Harbin Medical University in China. Informed consent was obtained from all patients. Specimens were collected and stored in liquid nitrogen immediately after surgery for further analysis. The study has been approved by the Research Ethics Committee of Harbin Medical University, China. The characteristics of the colorectal cancer tissues were demonstrated in Supplementary Table 2. Animal experiments All animals were maintained in a specific pathogen–free facility. The full length of the LISS (1081 nt) expression cassette was inserted into the Gt(ROSA)26Sor (Rosa26) locus (Chromosome 6: 113,076,031) through CRISPR/Cas9-mediated homologous recombination to generate LISSflox/flox mice by the Shanghai Model Organisms Center, Inc. C57BL/6-Tg (TcraTcrb) 1100Mjb/J (OT-1) mice, Apcmin/+ mice, and Villin-CreERT2 mice were originally purchased from the Jackson Laboratory. The female LISSflox/flox knock-in mice were crossed with male Villin-CreERT2 mice to generate intestinal epithelial cell-specific LISS expression mice (Villin-CreERT2; LISSflox/flox). The female Villin-CreERT2; LISSflox/flox mice were crossed with male Apcmin/+ mice to obtain Apcmin/+; Villin-CreERT2; LISSflox/flox mice. To induce the expression of LISS by tamoxifen, 6–7 week-old Apcmin/+; Villin-CreERT2; LISSflox/flox mice were intraperitoneally injected with tamoxifen at a dose of 100 mg per kg of body weight, injected once daily for five consecutive days. Male and female mice with or without tamoxifen treatment (n = 15/group) were randomly assigned to Apcmin/+; Villin-CreERT2; LISSflox/flox and Apcmin/+; Villin-CreERT2 groups and fed with the regular diet or high-fat diet (60% kcal from fat, Research Diets, Cat#D12492) started at the 7 weeks and ended at 20 weeks of age to promote colorectal adenoma development.42,43 For syngeneic mouse models, six-week-old C57BL/6 and BALB/c mice were randomly divided into different groups and subcutaneously injected with 5 × 105 colorectal cancer cells derived from their respective mouse strains (C57BL/6-derived MC38 and BALB/c-derived CT26 cells). To block CD8+ T cell function, an isotype or anti-CD8α antibody (100 μg/mouse, Bio X Cell, BP0117) was intravenously administered every other day for three weeks. For ICB, 100 μg/kg of an anti-PD1 monoclonal antibody (Bio X Cell, BE0273) or isotype IgG was administered into mice by intraperitoneal injection every 3 days in the presence of LISS-ASO (ASO) or Control-ASO (Con), encapsulated in lipid nanoparticles (40 mg/kg per dose) for three weeks. Tumor diameters were measured using callipers. Tumor volume was calculated by length×width×width/2. At the experimental endpoint (day 28), tumors were carefully excised, photographed, and weighed, with proteins and RNA isolated from tumor tissues and tumor-infiltrating T cells for subsequent analyses. All animal experiments were conducted according to the guidelines approved by the Institutional Animal Care and Use Committee of Harbin Institute of Technology. Lipid nanoparticle encapsulation of ASO ASO specifically targeting LISS and the control-ASO were purchased from RiboBio. The three nucleotides at both the 5′ and 3′ ends of the ASO sequence are composed of 2′−4′ cEt-modified ribonucleotides, which confer an increased affinity to the target mRNA and increased resistance to exo and endonucleases within the cell.44,45 Furthermore, the phosphorothioate backbone was used along the entire length of the ASO to give extra protection from the cellular exonucleases and endonucleases.46 Lipid nanoparticle packaged-ASO were prepared using a microfluidic mixing apparatus in the Nexstar. Briefly, all of the synthetic lipids, cholesterol, DOPE, and PEGylated lipids ordered from Sigma are included in the LNP formulation. The LNPs produced with colipids were referred to as formulated LNPs. To produce formulated LNPs, the synthesized lipid, cholesterol, DOPE, and DSPEPEG2000 were dissolved in ethanol and mixed in a weight ratio of 16/4/1/1. Then, 100 mL solution was added to 800 mL of sodium acetate buffer (25 mM, pH 5.2), and the production was mixed using a brief vortex. The formulation was subjected to dialysis for 2 h at room temperature using a 3.5 kDa MWCO membrane to remove ethanol. Finally, the formulated LNP solution was mixed with ASO at a weight ratio of 15/1 and incubated at room temperature before intraperitoneal injection in mice.35 ASOs were delivered to cancer cell lines using Lipofectamine 2000 (Invitrogen) at a final concentration of 60 nM. The ASO sequences were listed in the Supplementary Table 3. Supplementary information LISS enables immune evasion of colorectal cancers irrespective of MSI status Uncroped western blot Acknowledgements The work was funded by the National Key R&D Program of China (2022YFA1105200), the National Natural Science Foundation (No. 82403269), the China Postdoctoral Science Foundation (No. 2023M740931), and the Postdoctoral Fellowship Program (Grade C) of China Postdoctoral Science Foundation (No. GZC20233466). Author contributions Y.H. designed and supervised the project and wrote the paper. Q.L., X.W., W.Z., M.L., and G.H. performed the experiments. Q.L., G.H., H.L., S.Z., Z.X., and O.B. analyzed the data. M.W., Q.L., and X.W. performed animal experiments. Q.L. and L.L. collected clinical colorectal cancer samples and analyzed clinical data. Data availability Mass-spectrum data were deposited in the ProteomeXchange Consortium via the iProX partner repository under the following dataset identifiers: IPX0012501001. Additional data information is available from the corresponding authors upon reasonable request. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. These authors contributed equally: Qingyu Lin, Xingwen Wang Supplementary information The online version contains supplementary material available at 10.1038/s41392-026-02671-y. References Associated Data Supplementary Materials LISS enables immune evasion of colorectal cancers irrespective of MSI status Uncroped western blot Data Availability Statement Mass-spectrum data were deposited in the ProteomeXchange Consortium via the iProX partner repository under the following dataset identifiers: IPX0012501001. Additional data information is available from the corresponding authors upon reasonable request.